GLP-1 treatments reduce cancer risk in diabetes patients

A study shows type 2 diabetes patients on GLP-1 treatments like Ozempic have lower risk of 10 obesity-related cancers compared to those on insulin. The research, analyzing 1.6 million patients, suggests potential cancer prevention benefits. Newer GLP-1 drugs are more effective at controlling blood sugar and inducing weight loss. FDA-approved Ozempic in 2017. Studies on these drugs for cancer prevention are recommended.